OXBT - Oxygen Biotherapeutics, Inc. (NASDAQ) Stock - Page 12 - Stock Market Forum, Penny Stocks, FOREX, NASDAQ, AMEX, NYSE, Live Chat

**BadThad** · #**111** 06-10-2009, 10:32 AM

Generating some cash:

Quote:

Oxygen Biotherapeutics, Inc. Announces Private Placement Financing Agreement and Offer to Acquire Warrants
8:30a ET June 8, 2009 (PR NewsWire)
Oxygen Biotherapeutics, Inc. (OTC Bulletin Board: OXBO) today announced that the company has signed a securities purchase agreement and commenced an offer to acquire outstanding common stock purchase warrants. The shares of the company's common stock that are issued in the transactions described below will not be registered under the Securities Act of 1933, as amended, and may not be offered or sold in the United States absent registration or an applicable exemption from registration requirements. For additional information on the transactions described below, please see our Current Report on Form 8-K filed with the SEC on June 8, 2009, which is available on the SEC website at U.S. Securities and Exchange Commission (Home Page) and through the investor relations page of the company website at : : Oxygen Biotherapeutics, Inc : :.

Securities Purchase Agreement

Oxygen Biotherapeutics has signed a securities purchase agreement with Vatea Fund, Segregated Portfolio, an investment fund incorporated in the Cayman Islands. Under the agreement, Vatea Fund has agreed to purchase on July 10, 2009, 20 million shares of our restricted common stock for $5 million. The agreement establishes milestones for the achievement of product development and regulatory targets and other objectives, after which Vatea Fund is required to purchase additional shares of common stock at a price of $0.25 per share. Assuming all milestones are achieved, if less than 60 million outstanding common stock purchase warrants of Oxygen Biotherapeutics are acquired pursuant to the exchange offer described below, Vatea Fund is obligated to purchase 40 million additional shares for $10 million, but if more than 60 million warrants are acquired, Vatea Fund is obligated to purchase 60 million additional shares for $15 million.

Warrant Exchange Offer

On June 8, 2009, Oxygen Biotherapeutics commenced a limited offering to approximately 77 persons who hold 120,431,920 of our common stock purchase warrants to exchange the warrants for cash and restricted common stock of Oxygen Biotherapeutics. There is no minimum total number of warrants that must be offered for exchange to Oxygen Biotherapeutics by the holders. All offers for exchange must be delivered to Oxygen Biotherapeutics on or before July 9, 2009. Oxygen Biotherapeutics does not expect that it will accept for exchange more than approximately 80 million warrants due to budgetary constraints. Nevertheless, we reserve the right to accept and exchange all warrants offered, even if more than 80 million. For all but 2.7 million of the warrants we are offering to exchange for each warrant $0.04 in cash and one-half (1/2) share of restricted common stock. For the remaining 2.7 million warrants we are offering to exchange for each warrant $0.001 in cash and one-quarter (1/4) share of restricted common stock.

**BadThad** · #**112** 07-02-2009, 10:58 AM

Stock up 20% today on heavy volume.

**BadThad** · #**113** 07-13-2009, 11:09 AM

Stock up 10% today....in case you have not seen the chart for this one lately...here's a simple one:

**BadThad** · #**114** 07-20-2009, 03:49 PM

Stock up over 16% today. Some news I missed about $$$ coming in:

Quote:

Oxygen Biotherapeutics, Inc. Announces Closing of Private Placement Financing Agreement
8:30a ET July 16, 2009 (PR NewsWire)
Oxygen Biotherapeutics, Inc. (OTC Bullletin Board: OXBO) today announced that the company has closed on the first $5 million financing tranche with the Vatea Fund, Segregated Portfolio under a June 8, 2009 securities purchase agreement.

For additional details on the agreement, please see the Form 8-K filed with the SEC on June 8, 2009, which is available on the SEC website at U.S. Securities and Exchange Commission (Home Page) and through the investor relations page of the company website at : : Oxygen Biotherapeutics, Inc : :.

**BadThad** · #**115** 08-17-2009, 10:23 AM

Latest news:

Quote:

Oxygen Biotherapeutics, Inc. to Begin Oxycyte(R) Phase II Clinical Trials in Switzerland
6:00a ET August 14, 2009 (PR NewsWire)
Oxygen Biotherapeutics, Inc. (OTC Bulletin Board: OXBO) today announced that the company has received approval to begin a Phase II, dose escalation, clinical trial in Switzerland for use of Oxycyte(R) in traumatic brain injury (TBI). Oxycyte is the Company's perfluorocarbon (PFC) therapeutic oxygen carrier.

"This approval from Swissmedic means that we can begin enrolling patients," said Chris Stern, company chairman and CEO. "Our people have worked very hard to achieve this major milestone for our company. This trial is of invaluable importance in improving the outcome of patients with severe TBI. We hope to finally prove that there is a safe and effective treatment for this devastating injury."

The company has named the 128 patient study "Safety and Tolerability of Oxycyte in Patients with Traumatic Brain Injury" or "STOP TBI". The first patient is expected to be enrolled in September. Since study participants will all be emergency cases, it is not possible to pinpoint a date for the actual first patient.

A contract research organization (CRO), PFC Pharma Focus AG, will supervise the study. The principal investigator is Dr. Michael Reinert of the Department of Neurosurgery at the University Hospital of Berne. The Insel Hospital in Berne will be the first of the planned seven trial centers in Switzerland and four in Israel to begin enrolling patients. The other trial centers planned for the Swiss study are in Zurich, Aarau, St. Gallen, Basel, Geneva and Lausanne.

"We have a premier CRO to manage the Swiss trials and what I consider to be some of the best neurosurgeons in Switzerland as clinical investigators along with leading Swiss hospitals as study sites," said Stern. "Because of the way we are structuring the trials and the quality of the Swiss medical community, we should have data compliant with the requirements of a multi-national study that can be submitted to the FDA as well as Swissmedic."

The dose escalation studies will focus on finding the lowest dose of Oxycyte that provides clinical benefit in traumatic brain injury while minimizing adverse effects. Dose levels of Oxycyte would start at 1.0 ml/kg body weight and escalate in steps to 2.0 ml/kg, and 3.0 ml/kg for subsequent patient cohorts. Escalation of dose will only occur after a favorable review of safety data by an independent Data Safety Monitoring Board.

Zoom · #**116** 08-19-2009, 12:00 AM

Nice. Looks like you've been making some money, BT.
Good for you!

**greencat** · #**117** 09-07-2009, 08:42 PM

OXBO nice move as it broke over its old high.

OXBO Charts

**BadThad** · #**118** 09-08-2009, 03:02 PM

Stock up over 6% today on heavy volume. This one is going to a winner on a fundamental level. I'm deeply green on my holding.

Some news today:

Quote:

Oxygen Biotherapeutics, Inc. Submits Milestone Achievement Notice to Vatea Fund
8:30a ET September 8, 2009 (PR NewsWire)
Oxygen Biotherapeutics, Inc. (OTC Bulletin Board: OXBO) announced that it has formally notified Vatea Fund of the company's achievement of a milestone under the Securities Purchase Agreement dated June 8, 2009, as amended September 1, 2009. The milestone is a Clinical Trial for Oxycyte in Traumatic Brain Injury Approved by Swissmedic.

With the achievement of the milestone, the agreement calls for Vatea Fund to purchase 24 million shares of Oxygen Biotherapeutics stock from the company for $6 million with the transaction to close no later than December 10, 2009.

**greencat** · #**119** 09-17-2009, 08:51 AM

OXBO PROPOSES 15-1 REVERSE SPLIT

Oxygen Biotherapeutics, Inc. Posts Blog by CEO Chris Stern on Proposed Reverse SplitLast update: 9/17/2009 3:14:00 AMDURHAM, N.C., Sept 17, 2009 /PRNewswire-FirstCall via COMTEX/ -- Oxygen Biotherapeutics, Inc. (OXBO) has posted a new Blog entry by company chairman and CEO, Chris Stern. In the blog, Stern answers questions posed by shareholders regarding the company's proposed 1-for-15 reverse stock split. The Blog is available via a link on the home page of the company website at as well as via the Shareholder Forum link on the Investor Relations page of the website. About Oxygen Biotherapeutics, Inc. Oxygen Biotherapeutics, Inc. is dedicated to commercializing innovative pharmaceuticals and medical devices in the field of oxygen therapeutics and Defense Medicine(TM). The company has under development a perfluorocarbon (PFC) therapeutic oxygen carrier and liquid ventilation product (Oxycyte(R)) and has out-licensed an implantable glucose sensor. These products are based upon core technologies that include biomedical applications for PFCs as well as medical and industrial applications for biosensors. Each of the product candidates is designed with advantages over currently marketed products in major markets including traumatic brain injury, sickle cell crisis, trauma, wound care, decompression sickness, acute respiratory distress syndrome, stroke, myocardial infarction, surgery, diabetes wounds and ulcers, and cosmetic applications. More information is available at . SOURCE Oxygen Biotherapeutics, Inc.

**BadThad** · #**120** 09-17-2009, 04:26 PM

More infomation.....the dreaded R/S will hurt the stock.

Quote:

Oxygen Biotherapeutics, Inc. Seeks Shareholder Approval for Reverse Stock Split
8:30a ET September 9, 2009 (PR NewsWire)
Oxygen Biotherapeutics, Inc. (OTC Bulletin Board: OXBO) announced that the company's proxy, which is being mailed today, asks shareholders to approve a 1-for-15 reverse stock split at the annual meeting on Oct. 19, 2009.

"At last years' general annual meeting we explained the problems of being listed over the counter on the bulletin board and we promised to seek a listing change as soon as we can qualify," said Chris Stern, company chairman and CEO. "We are working toward meeting the listing standards of a major exchange. In that regard we are proposing a reverse split of our outstanding common stock in an effort to meet the minimum stock price qualification requirement of a major stock exchange."

At the meeting, shareholders also will vote on the election of six directors. The current directors have been nominated by the Board for re-election.

The proxy is being mailed today to shareholders of record on Sept. 4, 2009. A copy of the proxy is available on the Investor Relations page of the company website at Oxygen Biotherapeutics ? Employing Oxygen, Preserving Life!.